Core Viewpoint - North China Pharmaceutical announced a total external guarantee amount of approximately 1.701 billion yuan, which accounts for 31.56% of the audited net assets attributable to ordinary shareholders for the year 2024 [1] Group 1: Financial Guarantees - The company and its subsidiaries provided a total guarantee of approximately 1.611 billion yuan for its subsidiaries, representing 29.89% of the audited net assets for 2024 [1] - The guarantee amount for entities outside the consolidated financial statements is 90 million yuan, accounting for 1.67% of the audited net assets for 2024 [1] Group 2: Revenue Composition - For the first half of 2025, the revenue composition of North China Pharmaceutical is as follows: chemical preparations account for 42.67%, chemical raw materials account for 25.02%, biological preparations account for 16.71%, pharmaceutical and other logistics trade account for 6.76%, and pharmaceutical intermediates account for 6.47% [1] Group 3: Market Capitalization - As of the report date, the market capitalization of North China Pharmaceutical is 10.2 billion yuan [1]

Group 1 - The revenue composition of North China Pharmaceutical for the year 2024 is as follows: chemical preparations account for 44.02%, chemical raw materials account for 26.72%, biological preparations account for 16.36%, pharmaceutical intermediates account for 6.23%, and pharmaceutical and other logistics trade account for 4.61% [1] Group 2 - As of the announcement date, the total external guarantees provided by North China Pharmaceutical and its subsidiaries amount to approximately 1.757 billion yuan, which represents 32.6% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The company has provided guarantees totaling approximately 1.667 billion yuan for its subsidiaries, accounting for 30.93% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The amount of guarantees provided to entities outside the consolidated financial statements is 90 million yuan, which is 1.67% of the audited net assets attributable to ordinary shareholders for the year 2024 [3]